Review Article

You have free access to this content

How to optimize HCV therapy in genotype 1 patients: management of side-effects

  1. Angeli Chopra,
  2. Patricia L. Klein,
  3. Thia Drinnan,
  4. Samuel S. Lee*

Article first published online: 3 JAN 2013

DOI: 10.1111/liv.12080

Issue

Liver International

Liver International

Special Issue: Proceedings of the 6th Paris Hepatitis Conference, International Conference on the Management of Patients with Viral Hepatitis

Volume 33, Issue Supplement s1, pages 30–34, February 2013

Additional Information

How to Cite

Chopra, A., Klein, P. L., Drinnan, T. and Lee, S. S. (2013), How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver International, 33: 30–34. doi: 10.1111/liv.12080

Author Information

  1. University of Calgary Liver Unit, Calgary, Canada

* Correspondence
Dr S. S. Lee, 3330 Hospital Dr NW, Calgary, AB T2N 4N1, Canada
Fax: 1 403 270 0995
e-mail: samlee@ucalgary.ca

Publication History

  1. Issue published online: 3 JAN 2013
  2. Article first published online: 3 JAN 2013

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (125K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Benoit Chauvin, Sylvain Drouot, Aurélie Barrail-Tran, Anne-Marie Taburet, Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors, Clinical Pharmacokinetics, 2013,

    CrossRef

View Full Article (HTML) Get PDF (125K)